These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8882065)

  • 1. Serum cytokine and cytokine receptor levels in patients with giant cell arteritis during corticotherapy.
    Roblot P; Morel F; Lelievre E; Gascan H; Wijdenes J; Lecron JC
    J Rheumatol; 1996 Feb; 23(2):408-10. PubMed ID: 8882065
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Temporal arteritis].
    Rygvold O; Fauchald P
    Tidsskr Nor Laegeforen; 1973 Apr; 93(10):690-2. PubMed ID: 4755084
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum beta 2-microglobulin in temporal arteritis.
    Mulder H; De Jong GJ; Winckers PL; Schop C; Van der Waa G
    Neth J Med; 1982; 25(5):134-7. PubMed ID: 6178982
    [No Abstract]   [Full Text] [Related]  

  • 5. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.
    Hernández-Rodríguez J; Segarra M; Vilardell C; Sánchez M; García-Martínez A; Esteban MJ; Queralt C; Grau JM; Urbano-Márquez A; Palacín A; Colomer D; Cid MC
    Rheumatology (Oxford); 2004 Mar; 43(3):294-301. PubMed ID: 14679293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment.
    Carrie F; Roblot P; Bouquet S; Delon A; Roblot F; Becq-Giraudon B
    Arch Intern Med; 1994 Jul; 154(13):1521-4. PubMed ID: 8018008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum soluble CD23 levels in giant cell arteritis.
    Roblot P; Morel F; Lelièvre E; Biais-Sauvètre MH; de Groote D; Preud'homme JL; Lecron JC
    Immunol Lett; 1996 Oct; 53(1):41-4. PubMed ID: 8946216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
    Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of Horton's disease under corticotherapy].
    Graisely B; Audebert AA; Offret H; de Saint-Maur PP
    Nouv Presse Med; 1980 Oct; 9(37):2736. PubMed ID: 7433074
    [No Abstract]   [Full Text] [Related]  

  • 10. Giant cell arteritis--the methotrexate debate revisited.
    Rimar D; Rozenbaum M; Zisman D; Boulman N; Slobodin G; Eder L; Feld J; Rosner I
    J Rheumatol; 2006 Jul; 33(7):1458-9. PubMed ID: 16862661
    [No Abstract]   [Full Text] [Related]  

  • 11. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study.
    Salvarani C; Hunder GG
    Arthritis Rheum; 2001 Apr; 45(2):140-5. PubMed ID: 11324777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unusual presentations of giant cell arteritis (temporal arteritis).
    Fa'Amatuainu NA; Ng J; Kumar S; Green G
    Intern Med J; 2004 Nov; 34(11):654-5. PubMed ID: 15546466
    [No Abstract]   [Full Text] [Related]  

  • 13. High blood levels of chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment.
    Di Comite G; Previtali P; Rossi CM; Dell'Antonio G; Rovere-Querini P; Praderio L; Dagna L; Corti A; Doglioni C; Maseri A; Sabbadini MG; Manfredi AA
    Ann Rheum Dis; 2009 Feb; 68(2):293-5. PubMed ID: 19139212
    [No Abstract]   [Full Text] [Related]  

  • 14. Masked giant cell arteritis.
    Cheung PP; Richards G
    Aust Fam Physician; 2006 Nov; 35(11):893-5. PubMed ID: 17099811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course.
    Liozon E; Boutros-Toni F; Ly K; Loustaud-Ratti V; Soria P; Vidal E
    J Rheumatol; 2003 Jun; 30(6):1272-6. PubMed ID: 12784402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.
    Proven A; Gabriel SE; Orces C; O'Fallon WM; Hunder GG
    Arthritis Rheum; 2003 Oct; 49(5):703-8. PubMed ID: 14558057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Giant cell arteritis after the age of 75].
    Chevalet P; Masseau-Imbert A; Durand-Fix MH; Agard C; Brisseau JM; Rodat O; Barrier JH
    Ann Med Interne (Paris); 2002 Oct; 153(6):373-7. PubMed ID: 12486385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss.
    Cacoub P; Chemlal K; Khalifa P; Wechsler B; De Gennes C; Belmatoug N; Cohen P; Ziza JM; Verdoncq B; Piette JC
    J Rheumatol; 2001 Nov; 28(11):2474-9. PubMed ID: 11708421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A patient's diary.
    Ghose RR
    N Z Med J; 2005 Oct; 118(1224):U1718. PubMed ID: 16258587
    [No Abstract]   [Full Text] [Related]  

  • 20. Change of serum calcitonin in patients receiving glucocorticoids: an acute phase study.
    Mulder H; Hackeng WH; vd Lely AJ; Siersema-Smallegange M
    Neth J Med; 1990 Jun; 36(5-6):288-90. PubMed ID: 2395496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.